Advertisement

Psychopharmacology

, Volume 108, Issue 4, pp 485–494 | Cite as

Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in alzheimer's disease

  • G. M. M. Jones
  • B. J. Sahakian
  • R. Levy
  • D. M. Warburton
  • J. A. Gray
Original Investigations

Abstract

This single-blind, placebo controlled study reports on the effects of administering three acute doses of nicotine (0.4, 0.6 and 0.8 mg) subcutaneously to a group of Alzheimer's disease (DAT) patients (n=22), young adult controls (n=24), and normal aged controls (n=24). The study extends our previous findings obtained using smaller groups of subjects. Drug effects were examined on three computerised tests: the first measuring rapid visual information processing, sustained visual attention and reaction time (RVIP task); a delayed response matching to location-order task measuring sustained visual attention and visual short-term memory (DRMLO task); and a finger tapping test measuring simple reaction time (FT task). The critical flicker fusion test (CFF) was used as a measure of perception and the WAIS digit span forwards (DS), of auditory short-term memory. Tests were graded in difficulty, titrated to avoid floor and ceiling effects so that meaningful, direct comparisons between groups could be made. Nicotine significantly improved sustained visual attention (in both RVIP and DRMLO tasks), reaction time (in both FT and RVIP tasks), and perception (CFF task — both ascending and descending thresholds). Nicotine administration did not improve auditory and visual short-term memory. There were no consistent, overall patterns of difference in performance between smokers and non-smokers in the control groups, or between males and females in any group. Despite the absence of change in memory functioning, these results demonstrate that DAT patients have significant perceptual and visual attention deficits which are improved by nicotine administration. The importance of measuring multiple abilities in future drug studies is emphasized and results are discussed in terms of nicotine's actions on attention, information processing and short-term memory.

Key words

Nicotine Alzheimer's disease Attention Information processing Short-term memory 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Araujo D, Lapchak P, Collier B, Quirion S (1988) Characterization of N-[3H] methylcarbamylcholine binding sites and the effect of N-methylcarbamylcholine on acetylcholine release in rat brain. J Neurochem 51:292–299Google Scholar
  2. Brazell MP, Mitchell SN, Joseph MH, Gray JA (1990) Acute administration of nicotine increases the in vivo extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: comparison with caudate-putamen. Neuropharmacology 29:1177–1185Google Scholar
  3. Brazell MP, Mitchell SN, Gray JA (1991) Effect of acute administration of nicotine on in vivo release of noradrenaline in the hippocampus of freely moving rats: A dose-response and antagonist study. Neuropharmacology 30:823–833Google Scholar
  4. Broks P, Preston C, Traub P, Poppleton P, Ward C, Stahl SM (1988) Modelling dementia; effects of scopolamine on memory and attention. Neuropsychologia 28[5]:685–700Google Scholar
  5. Clarke P, Hamill G, Nadi N, Jacobowitz D, Pert A (1986) 3H-Nicotine and 125 I-alpha-bungarotoxin labelled nicotine receptors in the interpeduncular nucleus of rats. II. Effects of habenular deafferentation. J Comp Neurol 251:407–413Google Scholar
  6. Dunnett SB (1985) Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats. Psychopharmacology 87:357–363Google Scholar
  7. Hasenfratz M, Michel C, Nil R, Battig K (1989) Can smoking increase attention in rapid information processing during noise? Electrocortical, physiological and behavioural effects. Psychopharmacology 98:75–80Google Scholar
  8. Hinton D, Sadun A, Blanks J, Miller C (1986) Optic nerve degeneration in Alzheimer's disease. N Engl J Med 315[8]:485–487Google Scholar
  9. Hodges H, Allen Y, Sinden J, Lantos PL, Gray JA (1990) Cholinergic-rich foetal transplants improve cognitivie deficits in lesioned rats, but exacerbate response to cholinergic drugs. Prog Brain Res 82:347–358Google Scholar
  10. Hodges H, Allen Y, Sinden J, Mitchell SN, Arendt T, Lantos PL, Gray JA (1991) The effects of cholinergic drugs and cholinergic-rich foetal neural transplants on alcohol induced deficits in radial maze performance in rats. Behav Brain Res 43:7–28Google Scholar
  11. Hughes CP, Berg L, Danziger WL, Cohen LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 40:566–572Google Scholar
  12. Jones GMM (1990) The cholinergic hypothesis of dementia: the effects of lecithin and nicotine on human memory and attention. Doctoral thesis for the University of London, UKGoogle Scholar
  13. Jones GMM, Reith M, Philpot MP, Sahakian BJ (1987) Smoking and dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 50:1383Google Scholar
  14. Katz B, Rimmer S (1989) Ophthalmologic manifestations of Alzheimer's disease. Surv Ophthalmol 34:31–43Google Scholar
  15. Loeb M, Alluisi E (1984) Theories of Vigilance. In: Loeb M, Alluisi E (eds) Sustained attention in human performance. Wiley, Chichester, pp 179–395Google Scholar
  16. MacNab M, Folz E, Sweitzer J (1985) Evaluation of signal detection theory on the effects of psychotropic drugs on critical flicker-fusion frequency in normal subjects. Psychopharmacology 85:431–435Google Scholar
  17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS/ADRDA work group under the auspices of the Department of Health and Human Services Task force on Alzheimer's Disease. Neurology 34:939–944Google Scholar
  18. McNicol D (1972) A primer of signal detection. Allen & Unwin, LondonGoogle Scholar
  19. Mash DC, Flynn DD, Potter LT (1985) Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228:1115–1117Google Scholar
  20. Nelson H (1982) National Adult Reading Test (NART) manual. NFER-Nelson, WindsorGoogle Scholar
  21. Newhouse P, Sunderland T, Tariot P, Blumhardt C, Weingartner H, Mellow W (1988) Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 95:171–175Google Scholar
  22. Perry EK, Perry RH, Smith CJ, Purohit J, Bonham P, Dick D, Candy J, Edwardson JA, Fairburn A (1986) Cholinergic receptors in cognitive disorders. Can J Neurol Sci 13:521–527Google Scholar
  23. Perry EK, Perry RH, Smith CJ, Dick DJ, Candy JM, Edwardson JA, Fairburn A, Blessed G (1987) Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases. J Neurol, Neurosurg Psychiatry 50:806–809Google Scholar
  24. Philpot MP, Levy R (1987) A memory clinic for the early diagnosis of dementia. Int J Geriatr Psychiatry 2:195–200Google Scholar
  25. Royal College of Physicians (1983) Smoking or Health. Pitman Med, LondonGoogle Scholar
  26. Richard J, Araujo DM, Quirion R (1989) Modulation of cortical acetylcholine release by cholinergic agents. Soc Neurosci Abstr 15[2]:1197Google Scholar
  27. Russell M, Jarvis M, Jones G, Feyerabend C (1990) Nonsmokers show acute tolerance to subcutaneous nicotine. Psychopharmacology 102:56–58Google Scholar
  28. Sahakian BJ (1988) Cholinergic drugs and human cognitive performance. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology, vol 20, Psychopharmacology of the aging nervous system. Plenum Press, LondonGoogle Scholar
  29. Sahakian B, Jones G, Levy R, Gray J, Warburton D (1989) The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 154:797–800Google Scholar
  30. Sahgal A (1987a) Contrasting effects of vasopressin, desglycinamide-vasopressin and amphetamine on a delayed matching to position task in rats. Psychopharmacology 93:243–249Google Scholar
  31. Sahgal A (1987b) Some limitations of indices derived from signal detection theory: evaluation of an alternative index for measuring bias in memory tasks. Psychopharmacology 91:517–520Google Scholar
  32. Smith JM, Misiak H (1976) Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects — a review. Psychopharmacology 47:175–182Google Scholar
  33. van Duijn C, Hofman A (1991) Relation between nicotine intake and Alzheimer's disease. Br Med J 302:1491–1494Google Scholar
  34. Warburton D (1986) A state model for mental effort. In: Hockey GR, Gaillard AW, Coles MG (eds) Energetics of human information processing. Martinus Mijhof, Dordrecht, Netherlands, pp 217–232Google Scholar
  35. Warburton D (1988) Psychopharmacological aspects of nicotine. In: Russell M, Stolerman I, Wonnacott S (eds) Nicotine: actions and medical implications. Oxford University Press, Oxford, pp 119–131Google Scholar
  36. Warburton D (1989) Nicotine: an addictive substance or a therapeutic agent? Prog Drug Res 435:9–41Google Scholar
  37. Wechsler D (1955) WAIS manual. Psychological Corporation, NYGoogle Scholar
  38. Wesnes K, Warburton DM (1984) Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 82:147–150Google Scholar
  39. West RJ, Jarvis MJ (1986) Effects of nicotine on finger tapping rate in non smokers. Pharmacol Biochem Behav 25:727–731Google Scholar
  40. Wonnacott S, Russell MAH, Stolerman IP (1990) Nicotine psychopharmacology: molecular, cellular and behavioural aspects. Oxford Scientific Publications, Oxford University Press, OxfordGoogle Scholar
  41. Zilles K (1990) Codistribution of receptors in the human cerebral cortex. In: Mendelsohn FAO, Paxinos G (eds) Receptors in the human nervous system. Academic Press, LondonGoogle Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • G. M. M. Jones
    • 1
    • 2
  • B. J. Sahakian
    • 4
  • R. Levy
    • 1
  • D. M. Warburton
    • 3
  • J. A. Gray
    • 2
  1. 1.Department of PsychiatrySection of Old Age PsychiatryLondonUK
  2. 2.Department of PsychologyInstitute of PsychiatryLondonUK
  3. 3.Human Psychopharmacology Group, Department of PsychologyUniversity of Reading, Earley GateReadingUK
  4. 4.Department of PsychologyUniversity of CambridgeCambridgeUK

Personalised recommendations